Atrial natriuretic factor (1-28) (human, porcine) TFA  (Synonyms: Atrial natriuretic peptide (1-28) TFA)

Atrial natriuretic factor (1-28) (human, porcine) TFA exhibits blood pressure lowering activity by increasing sodium and urine excretion. Atrial natriuretic factor (1-28) (human, porcine) TFA inhibits the release of pituitary adrenocorticotropic hormone (ACTH) and beta-endorphin through inhibition of pro-opiomelanocortin (POMC) expression. Atrial natriuretic factor (1-28) (human, porcine) TFA increases cGMP levels in RMIC cells with an IC₅₀ of 1.2 nM^[1][2][3].

3080.46 (free base)

C₁₂₇H₂₀₅N₄₅O₃₉S₃.xC₂HF₃O₂

Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr

SLRRSSCFGGRMDRIGAQSGLGCNSFRY

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. B M Fontoura, et al. Atrial natriuretic factor receptors in cultured renomedullary interstitial cells. Am J Physiol. 1990 Apr;258(4 Pt 1):C692-9.  [Content Brief]

  [2]. T T Tan, et al. ANF(1-28) is a potent suppressor of pro-opiomelanocortin (POMC) mRNA but a weak inhibitor of beta EP-LI release from AtT-20 cells. J Endocrinol. 1994 Nov;143(2):R1-4.  [Content Brief]

  [3]. D M Pollock, et al. Beneficial effect of the ANF analog A68828 on recovery from ischemic acute renal failure. Ren Fail. 1992;14(2):141-6.  [Content Brief]